Avalo Therapeutics(DE:C6K0)
€6.98-0.51 (-6.81%)
DE:C6K0
Avalo Therapeutics stock forecast
€6.98
At close:-0.51 (-6.81%)
Avalo Therapeutics (C6K0) Stock Forecast & Price Target
0 Followers
C6K0 Analyst Ratings
Moderate Buy
5Buy2Hold0Sell
Based on 7 analysts giving stock ratings to Avalo Therapeutics in the past 3 months
C6K0 Stock 12 Month Forecast
Average Price Target
€23.59▲(237.91% Upside)Based on 7 Wall Street analysts offering 12 month price targets for Avalo Therapeutics in the last 3 months. The average price target is EUR 23.59 with a high forecast of EUR 54.43 and a low forecast of EUR 9.07. The average price target represents a 237.91% change from the last price of EUR 6.98.
Past 12 Months12 Month ForecastJan2026Oct2026
High€54.43
Average€23.59
Low€9.07
Highest Price TargetHighest€54.43Average Price Target€23.59Lowest Price TargetLowest€9.07
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Alec Stranahan | Bank of America Securities | €26.31→€21.77 | buy | 211.91%Upside | Reiterated | 11/06/26 | ||
| Mitchell Kapoor | H.C. Wainwright | ― | hold | ― | Reiterated | 11/06/26 | ||
| Robert Driscoll | Wedbush | €19.96→€18.14 | buy | 159.93%Upside | Reiterated | 11/06/26 | ||
| Julian Harrison | BTIG | €9.07 | buy | 29.96%Upside | Reiterated | 11/05/26 | ||
| Leland Gershell | Oppenheimer | €31.75→€14.51 | buy | 107.94%Upside | Reiterated | 10/26/26 | ||
| Yatin Suneja | Guggenheim | ― | hold | ― | Downgraded | 10/23/26 | ||
| Yasmeen Rahimi | Piper Sandler | €54.43 | buy | 679.79%Upside | Reiterated | 10/01/26 | ||
| Thomas Smith | Leerink Partners | €34.47 | buy | 393.86%Upside | Initiated | 07/06/26 | ||
| Stacy Ku | TD Cowen | ― | buy | ― | Reiterated | 06/11/26 | ||
| Alex Thompson CFA | Stifel Nicolaus | €32.66→€35.38 | buy | 406.86%Upside | Reiterated | 05/15/26 | ||
| Jason Butler | Citizens JMP | €56.24→€49.89 | buy | 614.80%Upside | Reiterated | 05/14/26 | ||
| Andy Chen | Wolfe Research | €43.54 | buy | 523.83%Upside | Initiated | 04/08/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Alec StranahanBank of America Securities | BuyReiterated€26.31→€21.77 | 11/06/26 | 211.91%Upside | ||
| Mitchell KapoorH.C. Wainwright | HoldReiterated | 11/06/26 | ― | ||
| Robert DriscollWedbush | BuyReiterated€19.96→€18.14 | 11/06/26 | 159.93%Upside | ||
| Julian HarrisonBTIG | BuyReiterated€9.07 | 11/05/26 | 29.96%Upside | ||
| Leland GershellOppenheimer | BuyReiterated€31.75→€14.51 | 10/26/26 | 107.94%Upside | ||
| Yatin SunejaGuggenheim | HoldDowngraded | 10/23/26 | ― | ||
| Yasmeen RahimiPiper Sandler | BuyReiterated€54.43 | 10/01/26 | 679.79%Upside | ||
| Thomas SmithLeerink Partners | BuyInitiated€34.47 | 07/06/26 | 393.86%Upside | ||
| Stacy KuTD Cowen | BuyReiterated | 06/11/26 | ― | ||
| Alex Thompson CFAStifel Nicolaus | BuyReiterated€32.66→€35.38 | 05/15/26 | 406.86%Upside | ||
| Jason ButlerCitizens JMP | BuyReiterated€56.24→€49.89 | 05/14/26 | 614.80%Upside | ||
| Andy ChenWolfe Research | BuyInitiated€43.54 | 04/08/26 | 523.83%Upside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Avalo Therapeutics
3 Months
Success Rate5/6 ratings generated profit
83%
Average Return
+6.67%
Copying Robert Driscoll's trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +6.67% per trade.
1 Year
Success Rate7/11 ratings generated profit
64%
Average Return
+35.07%
Copying Julian Harrison's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +35.07% per trade.
2 Years
Success Rate3/6 ratings generated profit
50%
Average Return
-19.27%
Copying Robert Driscoll's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of -19.27% per trade.
C6K0 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 13 | 6 | 5 | 8 | 7 |
| Buy | 1 | 1 | 0 | 1 | 2 |
| Hold | 0 | 0 | 1 | 3 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 14 | 7 | 6 | 12 | 13 |
In the current month, C6K0 has received 9 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. C6K0 average Analyst price target in the past 3 months is 23.59.
C6K0 Financial Forecast
High€-0.30
Consensus€-0.41
Low€-0.51
C6K0 Earnings Forecast
Next quarter’s earnings estimate for C6K0 is -EUR 0.41 with a range of -EUR 0.51 to -EUR 0.30. The previous quarter’s EPS was -EUR 0.31. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€0.00
Consensus€0.00
Low€0.00
C6K0 Sales Forecast
Next quarter’s sales forecast for C6K0 is EUR 0 with a range of EUR 0 to EUR 0. The previous quarter’s sales results were EUR 0. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
C6K0 Stock Forecast FAQ
What is DE:C6K0’s average 12-month price target, according to analysts?
Based on analyst ratings, Avalo Therapeutics’s 12-month average price target is €23.59.
What is DE:C6K0’s upside potential, based on the analysts’ average price target?
Avalo Therapeutics has 237.91% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Avalo Therapeutics a Buy, Sell or Hold?
Avalo Therapeutics has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 2 hold ratings and 0 sell ratings.
What is Avalo Therapeutics’s share price target?
The average share price target for Avalo Therapeutics is €23.59. This is based on 7 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €54.43, and the lowest forecast is €9.07. The average share price target represents a 237.91% increase from the current price of €6.98.
What do analysts say about Avalo Therapeutics?
Avalo Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Street analysts.
How can I buy shares of Avalo Therapeutics?
To buy shares of DE:C6K0, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
